Table 1 Demographics and JIIM baseline features (n = 70)*
From: The impact of the COVID-19 pandemic on patients with juvenile idiopathic inflammatory myopathies
N (%) | |
|---|---|
Sex | |
Female | 49 (70) |
Male | 20 (29) |
Prefer not to answer | 1 (1) |
Current age of JIIM patient | |
Under 5 | 5 (7) |
6–10 years | 22 (31) |
11–14 years | 20 (30) |
15–17 years | 11 (16) |
18–21 years | 12 (17) |
Race (n = 68) | |
White | 50 (74) |
Black/African American | 7 (10) |
American Indian | 1 (1) |
Asian | 2 (3) |
Other Race | 4 (6) |
Prefer not to answer | 4 (6) |
Ethnicity | |
Hispanic | 22 (31) |
Non-Hispanic | 45 (64) |
Prefer not to answer | 3 (5) |
JIIM Subtype (n = 62) | |
JDM | 59 (95) |
JPM | 3 (5) |
JIIM clinical manifestations at diagnosis (n = 62) | |
Skin Disease | 52 (84) |
Muscle Disease | 54 (87) |
Gastrointestinal Involvement | 7 (11) |
Lung Involvement | 9 (15) |
Heart Involvement | 6 (10) |
Joint Disease | 16 (26) |
JIIM autoantibodies (n = 63) | |
P155/140 (TIF-1) | 8 (13) |
MJ (NXP-2) | 5 (8) |
Jo-1 (anti-synthetase) | 2 (3) |
Mi-2 | 1 (2) |
MDA-5 (CADM-140) | 4 (6) |
Other | 3 (5) |
Negative Antibodies | 3 (5) |
Unknown or not done | 37 (59) |
Medications during 6 months prior to COVID-19 exposure/infection (n = 62) | |
Steroids | 25 (40) |
Methotrexate | 34 (55) |
Hydroxychloroquine | 26 (42) |
Intravenous immunoglobulin (IVIG) | 25 (40) |
Mycophenolate mofetil | 17 (27) |
Rituximab | 11 (18) |
Anti-TNF agent | 1 (2) |
Calcineurin Inhibitors | 2 (3) |
Other** | 6 (10) |
None of the above | 8 (13) |
Total number of immunosuppressive medications prior to exposure/infection with COVID-19 (n = 62) | |
None | 9 (15) |
One | 3 (5) |
Two | 24 (39) |
Three or more | 26 (42) |
*N = 70 participants, except where otherwise indicated. **Other medications include abatacept (n = 1), leflunomide (n = 1) and tofacitinib (n = 2). | |